CKD Bio Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
CKD Bio's earnings have been declining at an average annual rate of -121.1%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 3.6% per year.
Wichtige Informationen
-121.1%
Wachstumsrate der Gewinne
-121.1%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 11.3% |
| Wachstumsrate der Einnahmen | 3.6% |
| Eigenkapitalrendite | -17.6% |
| Netto-Marge | -14.5% |
| Letzte Ertragsaktualisierung | 30 Sep 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30Aufschlüsselung der Einnahmen und Ausgaben
Wie CKD Bio Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 23 | 159,935 | -23,130 | 15,057 | 16,277 |
| 30 Jun 23 | 155,183 | -20,233 | 15,377 | 15,272 |
| 31 Mar 23 | 152,876 | -18,403 | 15,251 | 15,341 |
| 31 Dec 22 | 156,042 | -16,703 | 15,513 | 15,432 |
| 30 Sep 22 | 154,395 | -10,462 | 13,971 | 13,939 |
| 30 Jun 22 | 154,759 | -11,222 | 13,750 | 12,777 |
| 31 Mar 22 | 155,569 | -5,821 | 13,246 | 11,940 |
| 31 Dec 21 | 142,238 | -6,577 | 12,585 | 11,516 |
| 30 Sep 21 | 135,760 | -6,730 | 12,105 | 10,878 |
| 30 Jun 21 | 130,483 | -1,111 | 11,355 | 10,667 |
| 31 Mar 21 | 127,741 | 1,771 | 11,109 | 10,114 |
| 31 Dec 20 | 124,600 | 6,207 | 10,538 | 9,118 |
| 30 Sep 20 | 135,773 | 10,664 | 9,873 | 9,900 |
| 30 Jun 20 | 138,042 | 12,633 | 9,852 | 10,455 |
| 31 Mar 20 | 136,265 | 12,446 | 9,718 | 10,584 |
| 31 Dec 19 | 137,184 | 12,265 | 10,057 | 10,704 |
| 30 Sep 19 | 129,529 | 10,563 | 9,913 | 9,919 |
| 30 Jun 19 | 127,134 | 9,605 | 9,347 | 9,074 |
| 31 Dec 18 | 124,510 | 7,956 | 8,530 | 7,881 |
Qualität der Erträge: A063160 is currently unprofitable.
Wachsende Gewinnspanne: A063160 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: Insufficient data to determine if A063160's year-on-year earnings growth rate was positive over the past 5 years.
Beschleunigtes Wachstum: Unable to compare A063160's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: A063160 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: A063160 has a negative Return on Equity (-17.58%), as it is currently unprofitable.